Physician profile
Richard E Roth
NPI 1366449977
$9,317.17
in general payments reported to CMS, 2019-2025
18 companies · $903 in 2025
The $903 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,522 · 2020: $339 · 2021: $486 · 2022: $1,240 · 2023: $1,443 · 2024: $2,385 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205 · Education: $1,500 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.04 |
| Education | $1,500.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,669.04 | 2019-2025 | Clareon, Argos, Ora System Verifeye |
| Merz North America, INC. | $2,405.73 | 2019-2025 | Xeomin |
| Rxsight INC | $1,904.77 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Carl Zeiss Meditec USA, INC. | $319.65 | 2021-2022 | |
| Abbvie INC. | $297.49 | 2023-2025 | |
| Allergan, INC. | $129.21 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $115.38 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $106.60 | 2025 | |
| Carl Zeiss Meditec, INC. | $90.66 | 2019 | |
| Ocular Therapeutix, INC. | $75.22 | 2024-2025 | Dextenza |
| New World Medical,INC. | $64.69 | 2024 | Streamline, Kahook Dual Blade, Clearpath |
| Rayner Intraocular Lenses Limited | $45.49 | 2022-2023 | Omidria, Rayone Emv, Rayone Aspheric |
| Revance Therapeutics, INC. | $23.57 | 2024 | Daxxify |
| Horizon Therapeutics Plc | $19.87 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $19.20 | 2021 | |
| Aerie Pharmaceuticals, INC. | $11.20 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.